The vaccine should be specially adapted to the omicron variant. The critical study on this begins in January.
The Mainz-based pharmaceutical company Biontech and its US partner Pfizer have started production of a corona vaccine adapted to the omicron variant for later commercial use. This was announced by Biontech boss Ugur Sahin on Tuesday at a health conference held by the US bank JP Morgan. A clinical trial for the vaccine will begin at the end of January.
“We expect to be ready to supply the market by March, once regulatory approvals are in place.” The European Medicines Agency (EMA) has not yet stated whether it considers an Omicron-adapted vaccine with a different composition than the vaccine currently used to be necessary.
For the year 2022, Biontech and Pfizer assume a production capacity of up to four billion vaccine doses worldwide. “We expect that there will also be strong demand for our vaccine in 2022,” Sahin said on his website.